Tamsulosin and floppy iris syndrome in benign prostatic hyperplasia patients

被引:5
|
作者
Tiwari, A [1 ]
机构
[1] Ranbaxy Res Labs, NDDR, Urol & Metab Grp, Gurgaon 122001, Haryana, India
关键词
5-HT receptors; benign prostatic hyperplasia; floppy iris syndrorne; iris prolapse; tamsulosin; alpha-blockers;
D O I
10.1517/13543784.15.4.443
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The American Society of Cataract and Refractive Surgery have cautioned ophthalmic surgeons of a new, sporadic problem associated with the pupil during cataract surgery in patients who are taking tamsulosin. The rare syndrome has been christened as intraoperative floppy iris syndrome (IFIS) by ophthalmologists. IFIS is characterised by subnormal preoperative pupil dilation and repeated intraoperative prolapse of a billowing, floppy iris in patients taking tamsulosin hydrochloride. Tamsulosin is the most commonly prescribed alpha-blocker for the treatment of benign prostatic hyperplasia in the ageing male population. Surprisingly, IFIS is not manifested in patients taking other alpha-blockers, such as terazosin, doxazosin or prazosin. The aetiology of IFIS with tamsulosin principally involves pharmacological mechanisms. Furthermore, there could be confounding factors (other than potency and selectivity of alpha-blockers for alpha(1)-adrenoceptors) that might be responsible for the association of IFIS with tamsulosin. IFIS will obviously have clinical implications in cataract surgery of benign prostatic hyperplasia patients with a medical history of tamsulosin use.
引用
下载
收藏
页码:443 / 446
页数:4
相关论文
共 50 条
  • [31] Tamsulosin in the management of patients in acute urinary retention from benign prostatic hyperplasia
    Lucas, MG
    Stephenson, TP
    Nargund, V
    BJU INTERNATIONAL, 2005, 95 (03) : 354 - 357
  • [32] A comparative study of terazosin and tamsulosin for symptomatic benign prostatic hyperplasia in Japanese patients
    Okada, H
    Kamidono, S
    Yoshioka, T
    Okuyama, A
    Ozono, S
    Hirao, Y
    Okajima, E
    Yamamoto, K
    Kishimoto, T
    Park, Y
    Kurita, T
    BJU INTERNATIONAL, 2000, 85 (06) : 676 - 681
  • [33] Clinical features, complications, and incidence of intraoperative floppy iris syndrome in patients taking tamsulosin
    Talamaz, T.
    Can, I.
    EUROPEAN JOURNAL OF OPHTHALMOLOGY, 2007, 17 (06) : 909 - 913
  • [34] Intracameral phenylephrine to prevent floppy iris syndrome during cataract surgery in patients on tamsulosin
    A Gurbaxani
    R Packard
    Eye, 2007, 21 : 331 - 332
  • [35] Development of microemulsion of tamsulosin and dutasteride for benign prostatic hyperplasia therapy
    Ciriaco, Shayara Lopes
    Santos Carvalho, Ivana Pereira
    Terceiro Neto, Jose Alves
    Lima Neto, Jose de Sousa
    Bento de Oliveira, Daniel Henrique
    Gomes Pereira Cunha, Ana Paula
    Duarte Cavalcante, Ykro Talvanis
    Casimiro da Silva, Dayane Tomaz
    da Silva, Jose Alexsandro
    Bezerra Barradas Mineiro, Ana Lys
    de Lima Chagas Moreno Fernandes, Maria Zenaide
    Menezes Carvalho, Andre Luis
    COLLOIDS AND SURFACES B-BIOINTERFACES, 2020, 185
  • [36] Tamsulosin Versus Terazosin for Benign Prostatic Hyperplasia: A Systematic Review
    Dong, ZhiLong
    Wang, ZhiPing
    Yang, KeHu
    Liu, YaLi
    Gao, WenHui
    Chen, WenYuan
    SYSTEMS BIOLOGY IN REPRODUCTIVE MEDICINE, 2009, 55 (04) : 129 - 136
  • [37] Effects of Tamsulosin on Premature Ejaculation in Men with Benign Prostatic Hyperplasia
    Choi, Jae Hwi
    Hwa, Jung Seog
    Kam, Sung Chul
    Jeh, Seong Uk
    Hyun, Jae Seog
    WORLD JOURNAL OF MENS HEALTH, 2014, 32 (02): : 99 - 104
  • [38] Tamsulosin and the risk of dementia in older men with benign prostatic hyperplasia
    Duan, Yinghui
    Grady, James J.
    Albertsen, Peter C.
    Wu, Z. Helen
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2018, 27 (03) : 340 - 348
  • [39] Evaluation of Safety and Efficacy of Alfuzosin and Tamsulosin in Benign Prostatic Hyperplasia
    Praveen, R.
    Kumar, T. N.
    Sen
    INDIAN JOURNAL OF PHARMACOLOGY, 2013, 45 : S119 - S120
  • [40] Dutasteride/tamsulosin: A guide to its use in benign prostatic hyperplasia
    Keating G.M.
    Drugs & Therapy Perspectives, 2013, 29 (4) : 91 - 96